Skip to main content
NKTR
NASDAQ Life Sciences

Nektar Therapeutics Secures Over $500M in Capital, Funds Phase 3 Trials Despite Q4 Losses

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$72.75
Mkt Cap
$1.969B
52W Low
$6.48
52W High
$75.67
52W Position info
1023% above low
Off High info
3.9% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NKTR has more than doubled off its 52-week low of $6.48.

Summary

Nektar Therapeutics reported a decline in Q4 2025 revenue and increased net loss, but announced a significantly strengthened financial position from recent capital raises totaling over $500 million, enabling the advancement of its lead clinical programs.


Key Events · Financing and Capital Events · NKTR

  • Q4 and Full Year 2025 Financial Results Reported

    Nektar Therapeutics reported Q4 2025 revenue of $21.8 million, down from $29.2 million in Q4 2024, and a net loss of $36.1 million ($1.78 per share) compared to net income of $7.3 million ($0.52 per share) in the prior year quarter. Full year 2025 revenue was $55.2 million, down from $98.4 million in 2024, with a net loss of $164.1 million ($9.73 per share).

  • Over $500 Million in New Capital Secured

    The company announced a significantly strengthened financial position, with cash and investments on December 31, 2025, at $245.8 million. This figure excludes approximately $432 million in net proceeds from a public offering completed in February 2026 and an additional $44 million from at-the-market (ATM) sales in February and March 2026, totaling over $500 million in new capital.

  • Key Pipeline Programs Advancing to Phase 3

    Nektar Therapeutics plans to initiate Phase 3 studies for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in Q2 2026. The company also highlighted positive Phase 2 data readouts for rezpegaldesleukin in atopic dermatitis and alopecia areata, and a new research collaboration with UCSF for NKTR-0165.


Analysis · NKTR · Life Sciences

This 8-K filing, while reporting a decline in Q4 2025 revenue and an increased net loss, highlights a critical strengthening of Nektar Therapeutics' financial position. The successful completion of a $460 million public offering and an additional $44 million from at-the-market sales provides substantial capital, significantly extending the company's cash runway. This funding is crucial for a clinical-stage biotech, enabling the planned initiation of Phase 3 studies for rezpegaldesleukin in atopic dermatitis and other pipeline advancements. Investors should focus on the company's enhanced ability to fund its key clinical programs, which de-risks future development despite the short-term financial performance.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NKTR was trading at $72.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $6.48 to $75.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NKTR - Latest Insights

NKTR
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $37.25
Real-time Price: $36.04 info
Change: -$1.22 (-3%) info
Market Cap: $1.234B info
NKTR
Oct 01, 2026, 11:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $48.58
Real-time Price: $36.04 info
Change: -$12.55 (-26%) info
Market Cap: $1.234B info
NKTR
Oct 01, 2026, 7:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $60.70
Real-time Price: $36.04 info
Change: -$24.67 (-41%) info
Market Cap: $1.234B info
NKTR
Oct 01, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $60.50
Real-time Price: $36.04 info
Change: -$24.47 (-40%) info
Market Cap: $1.234B info
NKTR
Sep 25, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.26
Real-time Price: $36.04 info
Change: -$26.23 (-42%) info
Market Cap: $1.234B info